Searched for
CDMO CAPACITY
Aragen steps up investment in complex drug modalities; plans 500 KL new CDMO capacityAragen Life Sciences is increasing investments in complex drug modalities and manufacturing. The company plans to add significant small-mol...- Jefferies hikes Navin Fluorine share price target, forecasts 14% upside. 4 reasons whyJefferies has retained its Buy rating on Navin Fluorine International and raised its price target to Rs 9,405, citing growth prospects in C...
- JM Financial sees up to 28% upside in Dr Reddy’s and Aurobindo Pharma. Should you buy?JM Financial retained Buy ratings on Dr Reddy’s Laboratories and Aurobindo Pharma, seeing up to 28% upside over the next 12 months. The bro...
- Global investing is no longer optional for Indian investors—but diversification is more than buying NVIDIA and Apple: Dhiraj RelliBut simply buying familiar names such as NVIDIA, Apple or Tesla does not automatically create a diversified international portfolio, warns ...
- How PGIM India's Rs 112 crore Healthcare Fund picks CDMO stocks to generate alphaPGIM India Healthcare Fund generated a 22% return over the past year by over-allocating to high-growth segments like CDMO, specialty pharma...
- Symbiotec Pharmalab IPO Day 4: GMP at 29%, subscription reaches 5.31xSymbiotec Pharmalab's IPO saw strong investor demand, closing oversubscribed 71.26 times. The company aimed to raise Rs 1,757 crore through...
- Convening India's brightest minds: The Bharat Life Sciences Award’s Innovation Summit to spotlight life sciencesIndia sets its sights on becoming a frontrunner in innovation within the life sciences arena. The Bharat Life Sciences Award 2026 aims to h...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsGiven the possibility of hostilities resuming in the Gulf region, focus on risk management in the market. Why? Because fresh hostilities wi...
- Symbiotec Pharmalab IPO Day 2: GMP signals 34% upside — Should you subscribe?Symbiotec Pharmalab's IPO saw robust investor demand, with the issue subscribed 1.85 times. The company aims to raise Rs 1,757 crore throug...
- Symbiotec Pharmalab’s Rs 1,757 crore IPO opens with GMP hinting at 41% upside. Should you bid?Symbiotec Pharmalab IPO GMP: Symbiotec Pharmalab’s Rs 1,757 crore IPO opened August 24, with a Rs 938–988 price band and 41% grey-market pr...
- NFO Insight: Invesco India Pharma and Healthcare Fund opens for subscription. Right time to invest in pharma funds?Invesco India has unveiled an innovative pharma and healthcare fund tailored for investors seeking opportunities in India's burgeoning heal...
- Can Symbiotec Pharmalab IPO deliver long-term growth for high-risk investors?Symbiotec Pharmalab plans a ₹150 crore IPO to repay debt and expand operations. The company holds a global leadership position in corticost...
- Strikes in the Gulf changing rules behind India’s big-money betsIndia Private Equity Investment 2026: Geopolitical risks now shape private equity deal considerations in India. Investors increasingly focu...
- Jefferies initiates coverage on Anthem Biosciences with a Rs 1,050 targetJefferies has initiated coverage on Anthem Biosciences with a Buy rating and Rs 1,050 target, implying around 20% upside. The brokerage is ...
- ETMarkets Smart Talk | Nifty enters ‘very attractive’ zone as earnings improve: Union AMC’s Sanjay BembalkarDespite muted foreign flows and persistent geopolitical uncertainties keeping a lid on the broader market, corporate earnings have remained...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsHere’s one thing to watch for in the next few weeks: How does the street treat disappointments in the mid-cap segment? If the reaction is l...
- Aarti Pharmalabs shares rally over 33% in two days post Q1 results. What is driving the surge?Aarti Pharmalabs shares have surged 33% in two days after the company reported a 65.4% year-on-year rise in Q1FY27 profit and 38.7% growth ...
- Gland Pharma shares rally 12% after Q1FY27 profit jumps 47% YoY. Should you buy, sell or hold?Gland Pharma shares rose sharply after Q1FY27 profit rose 47% and revenue grew 20% year-on-year. While strong margins and CDMO growth promp...
- Aarti Pharmalabs shares hit 20% upper circuit as Q1 net profit surges 65% YoY to Rs 76 croreAarti Pharmalabs shares hit the 20% upper circuit after the company reported a 65.4% year-on-year rise in Q1 FY27 net profit to Rs 76.14 cr...
- Gland Pharma inks strategic CDMO deal with global pharma firm, eyes $90-100 million annual revenueGland Pharma has signed a strategic Manufacturing and Supply Agreement with a leading global pharmaceutical company for technology transfer...
Load More
